Code | CSB-RA288083A0HU |
Size | US$210 |
Order now | |
Image |
|
Have Questions? | Leave a Message or Start an on-line Chat |
Application | Recommended Dilution |
---|---|
FC | 1:20-1:200 |
The RET recombinant monoclonal antibody preparation is based on protein technology and DNA recombinant technology. Mice are first immunized with a synthesized peptide derived from human RET. After a period of time, spleen cells are extracted under sterile conditions, and total RNA is extracted from the spleen cells. The cDNA synthesized by RNA reverse transcription is used as a template for PCR amplification of the RET antibody gene. The resulting gene is inserted into a vector, which is then transfected into host cells for cultivation. The RET recombinant monoclonal antibody is then purified from the cell culture supernatant by affinity chromatography. It has been thoroughly validated and can be used for the detection of human RET protein in ELISA and FC experiments.
The proto-oncogene tyrosine-protein kinase receptor RET is a receptor tyrosine kinase that plays a critical role in the development and function of the nervous system, kidney, and several other organs. RET is activated by its ligands such as GDNF, NRTN, ARTN, and PSPN, and undergoes dimerization and autophosphorylation on several tyrosine residues within its intracellular domain, which leads to the activation of downstream signaling pathways, including the RAS-RAF-MEK-ERK and PI3K-AKT pathways that play critical roles in cell proliferation, survival, differentiation, and migration. In addition to its role in development, RET mutations have been implicated in various human cancers, including medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and familial pheochromocytoma.
There are currently no reviews for this product.